Amneal stock rises
Amneal stock rises after FDA approves epinephrine injection
Amneal Pharmaceuticals Inc Class A stock rose 2.8% in after-hours trading Tuesday following the FDA approval of the company’s epinephrine injection USP, expanding its injectable medicine portfolio.
The newly approved treatment comes in both single-dose vials (1 mg/mL, 1 mL) and multi-dose vials (1 mg/mL, 30 mL) formats. Epinephrine is widely used in emergency and acute care settings for treating severe allergic reactions and managing hypotension in septic shock patients.
"Epinephrine is one of the most important and widely used emergency medicines in healthcare," said Arash Dabestani, Senior Vice President, Institutional at Amneal. "By bringing both single- and multi-dose vial presentations to the institutional market, we are helping expand reliable and affordable access for hospitals and clinical providers."
The approval strengthens Amneal’s position in the injectable medications market, particularly for critical care products used in hospital settings. According to IQVIA data cited by the company, U.S. annual sales for epinephrine injection single- and multi-dose vials reached approximately $118 million for the 12 months ended October 2025.
Epinephrine injection is indicated for emergency treatment of allergic reactions including anaphylaxis from insect stings, food allergies, drug reactions, and other allergens. It is also used to increase blood pressure in adult patients with hypotension related to septic shock.
The company noted that common adverse reactions may include anxiety, tremor, dizziness, sweating, palpitations, nausea, headache, and respiratory difficulties, with higher risk in patients with heart disease, hypertension, or hyperthyroidism.
